MedinCell S.A. (EPA:MEDCL)
France
· Delayed Price · Currency is EUR 16.79
+0.20 (1.21%)
Jun 27, 2025, 5:35 PM CET
MedinCell Revenue
In the fiscal year ending March 31, 2025, MedinCell had annual revenue of 27.73M EUR with 132.12% growth. MedinCell had revenue of 18.29M in the half year ending March 31, 2025, with 207.64% growth.
Revenue
27.73M
Revenue Growth
+132.12%
P/S Ratio
20.02
Revenue / Employee
211.66K
Employees
140
Market Cap
555.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 27.73M | 15.78M | 132.12% |
| Mar 31, 2024 | 11.95M | -1.71M | -12.52% |
| Mar 31, 2023 | 13.66M | 5.32M | 63.77% |
| Mar 31, 2022 | 8.34M | 152.00K | 1.86% |
| Mar 31, 2021 | 8.19M | 2.19M | 36.43% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 45.17B |
| Sartorius Stedim Biotech | 2.86B |
| bioMérieux | 3.98B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.40B |
| Clariane SE | 5.28B |
MedinCell News
- 4 months ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha